Johnson & Johnson (NYSE:JNJ) Shares Acquired by Werlinich Asset Management LLC

Werlinich Asset Management LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 1.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 13,330 shares of the company’s stock after purchasing an additional 200 shares during the period. Johnson & Johnson makes up 1.1% of Werlinich Asset Management LLC’s portfolio, making the stock its 25th largest position. Werlinich Asset Management LLC’s holdings in Johnson & Johnson were worth $1,911,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in JNJ. Cohen Investment Advisors LLC raised its position in Johnson & Johnson by 2.6% during the 4th quarter. Cohen Investment Advisors LLC now owns 19,530 shares of the company’s stock worth $2,824,000 after buying an additional 490 shares during the last quarter. Congress Park Capital LLC increased its stake in shares of Johnson & Johnson by 16.4% during the fourth quarter. Congress Park Capital LLC now owns 8,153 shares of the company’s stock worth $1,179,000 after acquiring an additional 1,151 shares during the period. Inspirion Wealth Advisors LLC raised its holdings in Johnson & Johnson by 7.3% during the fourth quarter. Inspirion Wealth Advisors LLC now owns 1,775 shares of the company’s stock worth $260,000 after purchasing an additional 120 shares in the last quarter. Tallon Kerry Patrick acquired a new stake in Johnson & Johnson in the fourth quarter valued at about $290,000. Finally, Mirador Capital Partners LP boosted its holdings in Johnson & Johnson by 5.5% in the 4th quarter. Mirador Capital Partners LP now owns 4,682 shares of the company’s stock valued at $677,000 after purchasing an additional 245 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on JNJ shares. Morgan Stanley raised their price target on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Bank of America reduced their target price on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating for the company in a report on Friday. Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday. Finally, Citigroup dropped their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $174.29.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $147.03 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The stock has a market cap of $353.99 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The business’s fifty day moving average price is $148.68 and its two-hundred day moving average price is $155.96. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.66 EPS. On average, analysts forecast that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ? increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.